• Visit the USI website
  • Go back to the homepage

Institute for Research in Biomedicine
Istituto di Ricerca in Biomedicina

Via Vincenzo Vela 6 - CH-6500 Bellinzona
Tel. +41 91 820 0300 - Fax +41 91 820 0302 - info [at] irb [dot] usi [dot] ch

Vaccine for Respiratory Syncytial Virus using Designed Protein Nanoparticle

Research area: Immune Regulation


Status: In progress

Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its identification as the main target of neutralizing antibodies, have provided new opportunities for development of an effective vaccine. We described the structure-based design of a self-assembling protein nanoparticle presenting a prefusion-stabilized variant of the F glycoprotein trimer in a repetitive array on the nanoparticle exterior. The two-component nature of the nanoparticle scaffold enabled the production of highly ordered, monodisperse immunogens that display DS-Cav1 at controllable density. In mice and nonhuman primates, the nanoparticle immunogen induced neutralizing antibody responses up to 10-fold higher than trimeric DS-Cav1.

Design, in vitro Assembly and Structural Characterization of DS-Cav1-I53-50. Schematic representation of the computational docking protocol with biophysical and structural characterization of the nanoparticles